Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Non interventional, Observational Post Marketing Surveillance under actual drug use condition.
Study drug and medical condition

Name of medicine, other

Encruse ELLIPTA
Population studied

Short description of the study population

This study was conducted in patients who were first prescribed Encruse for the approved indication, “relief of symptoms of obstructive airway disorder due to COPD (chronic bronchitis and emphysema)”.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Hepatic impaired
Other
Pregnant women
Renal impaired

Special population of interest, other

Chronic obstructive pulmonary disease (COPD) patients

Estimated number of subjects

1000
Study design details

Main study objective

This investigation will be conducted to collect and evaluate information regarding the safety and efficacy of Encruse ELLIPTA under the actual post-marketing use conditions of the product.

Outcomes

Information regarding the safety and efficacy of Encruse ELLIPTA under the actual post-marketing use conditions of the product.

Data analysis plan

Items related to patient dispositionPatient demographic and baseline characteristicsItems related to safetyItems related to efficacy